Initial observation of CIN2 does not appear to reduce quality of life in women under 25 years of age.

Katayoun TaghaviSára MorellJillian LambHelene MacNabCarrie InnesKate CoffeyJonathan WillimanBryony SimcockPeter Sykes

Published in: The Australian & New Zealand journal of obstetrics & gynaecology (2017)

We found no difference in HrQoL by management strategy. Conservative management of CIN2 in women under 25 is unlikely to have an adverse impact on self-reported HrQoL, anxiety or sexual functioning compared with conventional management.

Keyphrases

polycystic ovary syndrome
mental health
emergency department
pregnancy outcomes
pregnant women
metabolic syndrome
adipose tissue
physical activity
cervical cancer screening
electronic health record
adverse drug